Liminatus Pharma
LIMN | NASDAQ
$3.04
+$0.05 (+1.67%)
At close: Nov 16, 2026, 3:59 PM ET
$2.99
-$0.05 (-1.58%)
After-hours:
Nov 16, 2026, 7:41 PM ET
Liminatus Pharma Company Profile
Company profile explainedCompany Profile
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Key Executives
| Name | Position |
|---|---|
| Chris Kim | CEO, Chairman & President |
| Beom Kyu Choi | Chief Technology Officer & Member of Scientific Advisory Board |
| Scott Dam | Chief Financial Officer |
| Byong Chul Yoo | Chief Science Officer & Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 24, 2026 | 8-K | Current Report |
| Jul 22, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 14, 2026 | 4 | Filing |
| Jul 14, 2026 | SC 13D/A | [Amend] Filing |
| Jul 13, 2026 | DEF 14A | Filing |
Liminatus Pharma
| Country | United States |
| IPO Date | May 1, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Chris Kim |
Contact Details
12611 Hiddencreek Way Cerritos,
California 90703 United States
Stock Details
| Ticker Symbol | LIMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971387 |
| CUSIP Number | 53271X207 |
| ISIN Number | US53271X2071 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove LIMN